At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01177 SINO BIOPHARM
Market Closed 04-11 16:08:19
3.580
+0.140
+4.07%
High3.600Low3.410Vol109.15M
Open3.430D1 Closing3.440Amplitude5.52%
Mkt Cap67.20BTradable Cap67.20BTotal Shares18.77B
T/O384.62MT/O Rate0.58%Tradable Shares18.77B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Sino Biopharmaceutical Gets China Nod for Hematologic Tumor Drug Trial
MT Newswires Live  ·  04-10 09:56
Sino Biopharmaceutical Gets China Nod for Hematologic Tumor Drug Trial
BRIEF-Sino Biopharmaceutical Says Tqb3019 (Btk Protac) Approved For Clinical Trial By NMPA
Reuters  ·  04-09
BRIEF-Sino Biopharmaceutical Says Tqb3019 (Btk Protac) Approved For Clinical Trial By NMPA
Sino Biopharmaceutical - Tqb3019 (Btk Protac) Approved for Clinical Trial by Nmpa
THOMSON REUTERS  ·  04-09
Sino Biopharmaceutical - Tqb3019 (Btk Protac) Approved for Clinical Trial by Nmpa
Sino Biopharmaceutical's Anti-Tumor Drug Gets Implied Approval from China
MT Newswires Live  ·  04-04
Sino Biopharmaceutical's Anti-Tumor Drug Gets Implied Approval from China
BRIEF-Sino Biopharmaceutical Says Positive Results On Phase 3 Study Of Culmerciclib In Combination With Fulvestrant
Reuters  ·  03-24
BRIEF-Sino Biopharmaceutical Says Positive Results On Phase 3 Study Of Culmerciclib In Combination With Fulvestrant
Sino Biopharmaceutical - Positive Results on Phase Iii Study of Culmerciclib in Combination With Fulvestrant
THOMSON REUTERS  ·  03-24
Sino Biopharmaceutical - Positive Results on Phase Iii Study of Culmerciclib in Combination With Fulvestrant
Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$5.52 From HK$6.42, Keeps at Buy
MT Newswires Live  ·  03-21
Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$5.52 From HK$6.42, Keeps at Buy
Sino Biopharmaceutical's 2024 Attributable Profit Jumps 50%
MT Newswires Live  ·  03-20
Sino Biopharmaceutical's 2024 Attributable Profit Jumps 50%
BRIEF-Sino Biopharmaceutical Recommends Payment Of Final Dividend Of HK4 Cents Per Share
Reuters  ·  03-20
BRIEF-Sino Biopharmaceutical Recommends Payment Of Final Dividend Of HK4 Cents Per Share
Sino Biopharmaceutical - Recommended Payment of a Final Dividend of HK4 Cents per Share for Year
THOMSON REUTERS  ·  03-20
Sino Biopharmaceutical - Recommended Payment of a Final Dividend of HK4 Cents per Share for Year
Sino Biopharmaceutical - Recommended Payment of a Final Dividend of HK4 Cents per Share
THOMSON REUTERS  ·  03-20
Sino Biopharmaceutical - Recommended Payment of a Final Dividend of HK4 Cents per Share
Sino Biopharmaceutical - FY Revenue RMB28.87 Bln
THOMSON REUTERS  ·  03-20
Sino Biopharmaceutical - FY Revenue RMB28.87 Bln
Sino Biopharmaceutical's (HKG:1177) earnings have declined over five years, contributing to shareholders 43% loss
Simply Wall St.  ·  03-12
Sino Biopharmaceutical's (HKG:1177) earnings have declined over five years, contributing to shareholders 43% loss
Sino Biopharmaceutical's Drug Study Shows 85.2% Failure-Free Survival Rate for 12 Months
MT Newswires Live  ·  03-11
Sino Biopharmaceutical's Drug Study Shows 85.2% Failure-Free Survival Rate for 12 Months
BRIEF-Sino Biopharmaceutical Enters Exclusive Cooperation Agreement With Delova Biotech For QP001
Reuters  ·  03-06
BRIEF-Sino Biopharmaceutical Enters Exclusive Cooperation Agreement With Delova Biotech For QP001
Sino Biopharmaceutical - Entering Into an Exclusive Cooperation Agreement With Delova Biotech for Qp001
THOMSON REUTERS  ·  03-06
Sino Biopharmaceutical - Entering Into an Exclusive Cooperation Agreement With Delova Biotech for Qp001
Sino Biopharmaceutical - Expects That Product Will Be Approved by National Medical Products Administration of China for Marketing in Near Future
THOMSON REUTERS  ·  03-06
Sino Biopharmaceutical - Expects That Product Will Be Approved by National Medical Products Administration of China for Marketing in Near Future
BRIEF-Sino Biopharmaceutical Signs Exclusive Strategic Cooperation Agreement With Sciwind Biosciences
Reuters  ·  02-27
BRIEF-Sino Biopharmaceutical Signs Exclusive Strategic Cooperation Agreement With Sciwind Biosciences
Sino Biopharmaceutical - Signing of an Exclusive Strategic Cooperation Agreement With Sciwind Biosciences
THOMSON REUTERS  ·  02-27
Sino Biopharmaceutical - Signing of an Exclusive Strategic Cooperation Agreement With Sciwind Biosciences
Sino Biopharmaceutical - Co, Sciwind Biosciences Established Exclusivity on Licensing and Cooperation in 19 Countries for Human Interleukin-29 Project
THOMSON REUTERS  ·  02-27
Sino Biopharmaceutical - Co, Sciwind Biosciences Established Exclusivity on Licensing and Cooperation in 19 Countries for Human Interleukin-29 Project

Introduction

Company Name.
SINO BIOPHARM
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicine and Chemical Medicine segment is engaged in the manufacture, sale and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is principally engaged in the long term and short term investments. The Other segment is principally engaged in the related medical and hospital business.
Issue price:
--
Invest in Global Markets with Tiger Brokers!
Open App